海辰药业：公司注射用盐酸兰地洛尔被纳入国家医保目录

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]